Search

Your search keyword '"Fong, Caroline"' showing total 50 results

Search Constraints

Start Over You searched for: Author "Fong, Caroline" Remove constraint Author: "Fong, Caroline"
50 results on '"Fong, Caroline"'

Search Results

1. An AI based Digital Score of Tumour-Immune Microenvironment Predicts Benefit to Maintenance Immunotherapy in Advanced Oesophagogastric Adenocarcinoma

2. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

5. Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.

6. MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients

7. Genetic and immune landscape evolution in MMR‐deficient colorectal cancer

9. Genetic and immune landscape evolution in MMR‐deficient colorectal cancer.

11. MicroRNAs (miRs) as biomarkers of resistance to trastuzumab in HER2-positive oesophago-gastric cancer: Sub-study within the Planning Treatment for Oesophago-Gastric Cancer—A Randomised Maintenance Therapy Trial (PLATFORM).

13. Activity and toxicity of intramuscular 1000 iu /m 2 polyethylene glycol‐ E. coli L‐asparaginase in the UKALL 2003 and UKALL 2011 clinical trials

14. Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer

15. Investigating the prognostic value of TP53 and PIK3CA mutations in metastatic colorectal cancer (mCRC): Applying Structured Query Language (SQL) algorithms to real-world data from a high-volume U.K. tertiary cancer center.

18. Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.

19. Digital histological markers based on routine H&E slides to predict benefit from maintenance immunotherapy in esophagogastric adenocarcinoma.

20. Activity and toxicity of intramuscular 1000 iu/m2 polyethylene glycol‐E. coliL‐asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.

22. Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study.

23. SOlar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer.

24. Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma

31. Intramuscular PEG-Asparaginase At 1000 U/m2 Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol

42. Nucleic Acid Hybridization in the Diagnosis of Viral Infections

43. Kinetics of Nucleic Acid Synthesis in Human Embryonic Kidney Cultures Infected with Adenovirus 2 or 12: Inhibition of Cellular Deoxyribonucleic Acid Synthesis

48. Western Equine Encephalitis Mimicking Herpes Simplex Encephalitis

49. Intramuscular PEG-Asparaginase At 1000 U/m2Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol

50. Activity and toxicity of intramuscular 1000 iu/m 2 polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.

Catalog

Books, media, physical & digital resources